Neos Therapeutics Slides Despite FDA Approval
Neos Therapeutics saw its shares dip on Tuesday even thought it received approval from the FDA for its treatment of ADHD.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 165
Large Insider Buying at Alexion Raises Investors’ Eyebrows
Most of the large biotech outfits in America have gone into a limbo mode. Alexion Pharmaceuticals fits that bill despite its more than $26 billion market cap. Is it possible that some real good…
Egalet Stumbles Over FDA Complete Response Letter
Egalet saw its shares take a dive early on Tuesday after the company announced that it received a complete response letter FDA in regards to its chronic pain treatment.
Dova Pharmaceuticals Closes in on IPO
Dova Pharmaceuticals intends to price its about 4 million shares in the range of $15 to $17 in an initial offering valued up to more than $79 million.
Akcea Therapeutics Announces Potential Pricing for IPO
Akcea Therapeutics expects to price more than 9 million shares in the range of $12 to $14 apiece in an initial public offering valued up to almost $155 million.
Rigel Pharma Rises Following FDA Approval
Rigel Pharmaceuticals watched its shares make a handy uptick on Monday after the FDA approved its New Drug Application for the use of Tavalisse in patients with chronic or persistent immune thrombocytopenia.
Is This the Buyout Novadaq Needs?
Novadaq Technologies watched its shares practically double to kick off the week after the firm announced that it would be acquired by Striker.
Clovis Oncology Surges on Clutch Late-Stage Ovarian Cancer Trial
Clovis Oncology saw its shares make a massive gain early on Monday after the company announced top-line data from its confirmatory Phase 3 trial of its treatment of ovarian cancer.
Aurinia Pharma Rises Following Updated Mid-Stage Results
Shares of Aurinia Pharmaceuticals saw a handy gain on Friday after the firm presented new data from its mid-stage study in lupus nephritis during the Annual European Congress of Rheumatology.
Mersana Therapeutics Closes in on IPO After Announcing Expected Price Range
Mersana Therapeutics expects to price its 5 million shares in the range of $14 to $16 apiece in an initial public offering valued up to $92 million.
Aldeyra Stumbles Over Mid-Stage Clinical Results
Aldeyra Therapeutics saw its shares slide on Wednesday after the company said its allergic conjunctivitis drug missed the primary endpoint in this Phase 2b trial.
Alexion Pharmaceuticals Adds New CFO From Biogen
Shares of Alexion Pharmaceuticals saw a handy gain early on Wednesday after the company announced that there would be changes in its leadership.
How Omeros Won Big on This FDA Approval
Omeros saw its shares make a handy gain on Tuesday after the company announced that the FDA granted a Breakthrough Therapy designation for its treatment for IgA nephropathy.
Acceleron Pharma Slides on Missed Mid-Stage Results
Acceleron Pharma saw its shares droop early on Tuesday after the firm offered an update from its mid-stage trial in advanced renal cell carcinoma.
Why Coherus Biosciences Shares Are Crashing
Coherus Biosciences saw its shares crater on Monday after the company announced that it received a complete response letter from the FDA regarding its biologics license application for a pegfilgrastim (Neulasta) biosimilar candidate.